GlaxoSmithKline's inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a large clinical trial.
The study tested the drug on 16,485 chronic obstructive pulmonary disease (COPD) patients with moderate airflow limitation.
Breo was approved in 2013 for COPD, but sales have been slow. Investors had hoped the large study would help boast sales.
Study resutls did reveal that Breo lowered the risk of dying by 12.2 percent compared to placebo, but the difference was not big enough to be deemed statistically significant.
Read the Tech Times article